Boron-containing compounds, addition

For successful treatment of cancer by BNCT, it is, however, not enough that the liposomes collect in tumour tissue. For best effect the liposomes should specifically bind to, and be internalised by, the tumour cells. In addition, it is important that the boron-containing compound, after its release from the internalised liposome, is retained within the cell and preferably localises within the cell nucleus. 

Molecules that are suitable as probes for two-photon fluorescence microscopy in terms of efficient emission, solubility, and nontoxicity are being rapidly developed and have been applied to various fields. Compounds above (Scheme 9.9) and further analogs show cpf>0.86, 5 >200 GM in the NIR region, are rather photostable, and have been shown to localize specifically in distinct areas of the cell. On the other hand, boron-containing compounds of structure 22 (Scheme 9.10) are also taken up by cells, likewise show 8 > 200 GM in the NIR region, and have the additional advantage of the possible use in boron neutron capture therapy [33]. 

Boron-containing compounds, especially those with only three substitutions, are mostly known for their functions as anion receptors. However, some of these compounds are also capable of forming an SEl, making them bi-functional additives [78]. The lithium salts with tetra-substituted boron anions such as LiBOB and LiDFOB can serve as SEI-forming additives in electrolytes based on other salts... 

The successful application of boron neutron capture therapy (BNCT) is dependent on the identification and preparation of boron-containing compounds that can be delivered to and retained by the tumor in significant amounts (>15 pg boron/g tumor) (Fairchild and Bond, 1985). Compounds targeted for application in BNCT must either accumulate in the tumor through natural mechanisms or, in the case of compounds that have no natural propensity for the tumor, be delivered to the tumor using a tumor-specific delivery modality. In addition to the required tumor boron concentration, the selected compounds should yield in vivo biodistributions with tumor to normal tissue (including blood) ratios of three or higher and be sufficiently nontoxic (Hawthorne, 1993 Soloway et al., 1998). 

Boron-containing compounds as additives to increase high ionic conductivity. 

The product is obtained in 95% yield and 94% ee. In the counterpart in solution, the ee was only 21-50%. Polymeric chiral catalysts have also been used in the addition of zinc alkyls to aldehydes. Use of a proline-based copolymer in a continuous asymmetrical synthesis with an ultra filtration membrane gave 80% ee (10.61).138 There was no deactivation in 7 days. A boron-containing polymer (10.62) gave only 28-51% ee compared with the 65-75% ee found with model compounds in solution.139... 

A new boron-nitrogen ring compound, a cyclohexadecaborazane containing in addition four six-membered borazine systems (52) has now been prepared from... 

Boron trifluoride forms complexes with oxygen-containing compounds, like water, alcohols, and ethers. When it initiates the polymerization of epoxides, it can associate simultaneously with several different moieties. These are the monomeric cyclic ethers, as well as the open-chain polymeric ether groups, and the hydroxy groups on the chain ends. In addition, it can also associate with the hydroxy groups of water. The following illustration shows the type of equilibrium that can take place ... 

---